pembrolizumab
merck
['improve ', 'melanoma', 'key,note,24', 'pembro']
#esmo22 presidential session: keynote-414: adding pembro to qt/rt in la #hnscc did not improve efs hr 0.83 swog s1801: neoadjuvant vs adjuvant pd-1 in stage iiib-iv in melanoma favours neoadjuvant with a 74% vs 49% event-free at 24 months hr 0.5 
Medical Oncologist MD, BSc Vall d'Hebrón @vallhebron @VHIO

Vicepresident Secció Metges MIR del COMB @COMBarcelona 

Asesor @SalutUIC

#oncology #research #MIR